|

CG001419 tablets Clinical Trials

1 actively recruiting trial

Pipeline

Phase 1/2: 1

Top Sponsors

  • Cullgen (Shanghai),Inc1

Indications

  • NTRK Fusion Positive1
  • NTRK Gene Fusion1
  • NTRK1
  • Solid Tumors Harboring NTRK Fusion1
  • Cancer1

Other1 trial

A Phase 1/2 Study of CG001419 Tablets in Adult Subjects With Locally Advanced or Metastatic Solid Tumours Harbouring NTRK Gene Abnormalities
Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.